New long-term data from the BELIEVE trial confirm that luspatercept, manufactured by Bristol Myers Squibb, provides lasting benefits for patients with transfusion-dependent beta-thalassemia, significantly reducing the need for frequent blood transfusions. Patients taking luspatercept had a median 33% reduction in transfusion burden lasting 586 days — nearly 3.5x longer than those on placebo (171 days). Additionally, 77% of patients achieved a 33% or greater reduction in transfusions over 12 weeks, compared to 35% with the placebo. Moreover, iron levels improved, with ferritin — a marker of iron overload — decreasing by over 400 µg/L, which helped reduce complications associated with excess iron. Safety remained manageable, with side effects decreasing over time. Beta-thalassemia patients often rely on regular blood transfusions, leading to iron overload, liver damage, and other serious complications. Luspatercept offers a durable solution, cutting transfusion needs and improving quality of life.

At OxyDial, we’re encouraged by these results, which highlight progress in treating chronic blood disorders. This breakthrough reinforces the importance of innovative treatments for genetic blood diseases, bringing us closer to better, long-term care for patients.

Read more: https://www.hematologyadvisor.com/news/beta-thalassemia-luspatercept-durable-efficacy-treatment-ris/

#BetaThalassemia #SickleCell #BloodDisorders #Hematology #MedicalBreakthrough #Luspatercept #IronOverload #TransfusionFree #PatientCare #OxyDial #MedicalInnovation